Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) fell 4.8% during trading on Monday . The company traded as low as $2.61 and last traded at $2.77. 2,070,560 shares were traded during trading, an increase of 110% from the average session volume of 987,783 shares. The stock had previously closed at $2.91.
Phio Pharmaceuticals Stock Performance
The firm has a market capitalization of $4.13 million, a P/E ratio of -0.25 and a beta of 1.51. The stock has a fifty day moving average price of $2.48 and a two-hundred day moving average price of $3.02.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
Read More
- Five stocks we like better than Phio Pharmaceuticals
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- Top Biotech Stocks: Exploring Innovation Opportunities
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
